49 Chondrosarcoma, a primary malignant bone tumour, has long posed significant challenges due to its complex nature and resistance to conventional treatments. Recent years have witnessed a notable increase in global research focused on understanding and combating this disease. A new bibliometric analysis reveals crucial trends in chondrosarcoma research, spotlighting the latest advancements and highlighting areas of focus that are shaping future therapeutic strategies. The findings were published in the journal Frontiers in Pharmacology. From 2003 to 2022, over 4,000 studies on chondrosarcoma were published, marking a steady increase in research activity. The US and China have emerged as leaders in this field, contributing significantly to the global research output. The analysis points to a collaborative trend, with institutions in these countries leading in both publication volume and research influence. However, the study also indicates a need for greater international cooperation, as the current landscape shows limited cross-border collaboration. China’s rapid rise in research output is particularly notable. From just 25 publications in 2003, the country has seen a significant increase in chondrosarcoma-related studies, now consistently contributing around 50 articles annually since 2015. Despite this growth, the influence of Chinese research remains limited on the global stage, underscoring the importance of enhancing academic exchanges with other nations. The study identifies several key areas of interest that have dominated recent chondrosarcoma research. These include genetic mutations, signal pathways, immunotherapy, proton therapy, chemotherapy, and surgical advancements, each offering new avenues for treatment.Researchers have increasingly focused on genetic mutations in chondrosarcoma, with particular attention to the IDH1/2 genes, which are frequently mutated in this cancer. These mutations have opened the door to targeted therapies, such as IDH inhibitors, which are currently being explored in clinical trials. As research continues, it is anticipated that these inhibitors could soon play a crucial role in treating chondrosarcoma, offering a more personalised approach to therapy. Signal pathways, including the PI3K-AKT mTOR pathway and the Hedgehog (Hh) pathway, are also at the forefront of current research. These pathways are critical in regulating tumour growth and proliferation, and their inhibition has shown promise in preclinical studies. Although clinical trials have faced challenges, particularly with Hh pathway inhibitors, ongoing research aims to refine these approaches and improve their efficacy. Proton therapy is gaining traction as a potential game-changer in treating skull base chondrosarcomas, which are particularly difficult to manage due to their deep location and high recurrence rates. This advanced form of radiation therapy offers precise targeting, which minimises damage to surrounding healthy tissues, making it a promising option for patients with inoperable or recurrent tumours. The study highlights the need for further research into the long-term outcomes of proton therapy, particularly its application in combination with other treatment modalities. While immunotherapy has revolutionised treatment for many cancers, its application in chondrosarcoma is still in its early stages. The study notes that checkpoint inhibitors, such as PD-1 inhibitors, have shown some efficacy in clinical trials, but more research is needed to fully understand their potential in this context. The combination of immunotherapy with traditional treatments like chemotherapy and radiation therapy is a promising area of exploration, potentially leading to more effective treatment protocols. Surgery remains the cornerstone of chondrosarcoma treatment, especially for localised tumours. Advances in 3D printing technology are transforming surgical approaches, allowing for the creation of custom prostheses that improve functional outcomes for patients undergoing complex pelvic reconstructions. However, the high cost and technical challenges associated with 3D printing limit its widespread use. The study suggests that future research should focus on improving the accessibility and affordability of these technologies to enhance patient outcomes globally. Despite significant progress, the study underscores several challenges that continue to hinder advancements in chondrosarcoma treatment. These include the disease’s inherent resistance to chemotherapy, the limited effectiveness of radiation therapy in certain tumour locations, and the need for more effective systemic treatments for metastatic disease. Looking ahead, the research community is expected to place greater emphasis on collaborative efforts that bridge the gap between basic research and clinical application. The integration of novel therapies, such as gene editing and personalised medicine, into standard treatment protocols could revolutionise the management of chondrosarcoma in the coming years. As research into chondrosarcoma continues to evolve, the focus will likely shift towards multidisciplinary approaches that combine advances in genetics, immunology, and surgical techniques. These efforts aim to improve survival rates and quality of life for patients battling this challenging form of cancer.